Affiliation: Actelion Pharmaceuticals Ltd
- Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexantP Hoever
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
Clin Pharmacol Ther 87:593-600. 2010..Population pharmacokinetic/pharmacodynamic modeling suggested that doses of ~500 mg almorexant and 10 mg zolpidem are equivalent with respect to subjectively assessed alertness...
- Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trialP Hoever
Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
Clin Pharmacol Ther 91:975-85. 2012..placebo. Adverse-event incidence was dose-related. Almorexant consistently and dose-dependently improved sleep variables. The orexin system may offer a new treatment approach for primary insomnia...